Loading…
Alta Pharma (ალტა ფარმა) — a Georgian pharmaceutical company (founded ~2021) whose registered activity (per reportal.ge) is both retail sale of pharmaceutical goods in specialised stores and wholesale of pharmaceutical goods (NACE 46.46). Its high gross and net margins point to a branded-import / representation business alongside retail.
| Ratio | 2022 | 2023 | 2024 |
|---|---|---|---|
| Margins | |||
| Gross Margin | 53.5% | 52.3% | 62.3% |
| EBITDA Margin | 46.7% | 45.9% | 38.4% |
| EBITDAR | 1,386 | 1,602 | 1,510 |
| EBITDAR Margin | 47.7% | 46.4% | 38.6% |
| EBIT Margin | 46.7% | 45.9% | 38.4% |
| Net Profit Margin | 46.7% | 43.2% | 30.3% |
| Operating Expense % of Sales | 6.8% | 6.4% | 23.9% |
| Returns | |||
| Return on Assets (ROA) | 92.1% | 54.1% | 30.0% |
| Return on Equity (ROE) | 105.6% | 55.4% | 31.5% |
| ROIC [EBIT / Invested Capital] | 152.0% | 61.3% | 41.1% |
| Leverage & debt balances | |||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 87.2% | 97.8% | 95.3% |
| Net Debt | -393 | -106 | -113 |
| Cash & Equivalents | 393 | 106 | 113 |
| Total Debt | N/A | N/A | N/A |
| Liquidity & working capital | |||
| Current Ratio | 8.24x | N/A | 28.70x |
| Quick Ratio | 8.24x | N/A | 29.45x |
| Cash Ratio | 2.19x | N/A | 0.82x |
| Total Current Assets | 1,476 | 2,756 | 3,952 |
| Total Current Liabilities | 179 | N/A | 138 |
| Inventory | N/A | -77 | -102 |
| Trade Receivables | 642 | 2,349 | 3,315 |
| Trade Payables | 179 | N/A | 138 |
| Net Working Capital | 1,297 | 2,756 | 3,815 |
| Net Working Capital % of Revenue | 44.6% | 79.8% | 97.5% |
| Trade Working Capital | 463 | 2,273 | 3,075 |
| Trade Working Capital % of Revenue | 15.9% | 65.8% | 78.6% |
| Change in Trade Working Capital | N/A | 1,809 | 802 |
| Turnover & efficiency | |||
| Inventory Turnover | N/A | -21.49x | -14.40x |
| Days Inventory Outstanding (DIO) | N/A | -17.0 | -25.3 |
| Receivables Turnover | 4.52x | 1.47x | 1.18x |
| Days Sales Outstanding (DSO) | 80.7 | 248.3 | 309.2 |
| Payables Turnover | 7.55x | N/A | 10.72x |
| Days Payable Outstanding (DPO) | 48.4 | N/A | 34.1 |
| Cash Conversion Cycle | 32.3 days | 231.3 days | 249.8 days |
| Asset Turnover | 1.97x | 1.25x | 0.99x |
| Cash flow & dividends | |||
| Operating Cash Flow | 379 | -287 | 8 |
| Free Cash Flow (OCF − Capex proxy) | 379 | -287 | 8 |
| Cash Conversion (OCF / EBITDA) | 27.9% | -18.1% | 0.5% |
| Dividends Declared | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →